XML 32 R21.htm IDEA: XBRL DOCUMENT
v3.23.2

Shares and Stockholders' Equity | 6 Months Ended
--- | ---
Jun. 30, 2023
Shares and Stockholders' Equity [Abstract] |
Shares and Stockholders' Equity | 15. Shares and Stockholders’ Equity Preferred Shares Preferred stock authorized, issued and outstanding (number of shares) was as follows:
| As of June 30, 2023 |  | As of December 31, 2022
| Shares Authorized |  | Shares Issued |  | Shares Outstanding |  | Shares Authorized |  | Shares Issued |  | Shares Outstanding
9.250% Fixed Rate Reset Non-Cumulative |  |  |  |  |  |  |  |  |  |  |
Preferred Stock, Series C | 20,000 |  | 20,000 |  | 20,000 |  | 20,000 |  | 20,000 |  | 20,000
9.000% Non-Cumulative Preferred Stock, Series D | 20,000 |  | 20,000 |  | 20,000 |  | 20,000 |  | 20,000 |  | 20,000
Not designated | 9,960,000 |  | - |  | - |  | 9,960,000 |  | - |  | -
Total preferred shares | 10,000,000 |  | 40,000 |  | 40,000 |  | 10,000,000 |  | 40,000 |  | 40,000
The per share and aggregate dividends declared for preferred stock by series (in millions except per share data) was as follows:
|  | For the Three Months Ended June 30, |
|  | 2023 |  |  | 2022 |
|  | Dividend |  |  | Aggregate |  |  | Dividend |  |  | Aggregate |
Series |  | Per Share |  |  | Dividend |  |  | Per Share |  |  | Dividend |
Series C | $ | - |  | $ | - |  | $ | - |  | $ | - |
Series D |  | 562.50 |  |  | 11 |  |  | - |  |  | - |
Total | $ | 562.50 |  | $ | 11 |  | $ | - |  | $ | - |
|  | For the Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |
|  | Dividend |  |  | Aggregate |  |  | Dividend |  |  | Aggregate |
Series |  | Per Share |  |  | Dividend |  |  | Per Share |  |  | Dividend |
Series C | $ | 635.94 |  | $ | 13 |  | $ | - |  | $ | - |
Series D |  | 1,181.25 |  |  | 23 |  |  | - |  |  | - |
Total | $ | 1,817.19 |  | $ | 36 |  | $ | - |  | $ | - |
Common Shares The changes in our common stock (number of shares) were as follows:
| For the Three |  | For the Six |
| Months Ended |  | Months Ended |
| June 30, |  | June 30, |
| 2023 |  | 2022 |  | 2023 |  | 2022 |
Common Stock |  |  |  |  |  |  |  |
Balance as of beginning-of-period | 169,537,759 |  | 171,890,974 |  | 169,220,511 |  | 177,193,515 |
Stock compensation/issued for benefit plans | 93,121 |  | 161,566 |  | 410,369 |  | 676,421 |
Retirement/cancellation of shares | - |  | (1,828,424 | ) | - |  | (7,645,820 | )
Balance as of end-of-period | 169,630,880 |  | 170,224,116 |  | 169,630,880 |  | 170,224,116 |
Common Stock as of End-of-Period |  |  |  |  |  |  |  |
Basic basis | 169,630,880 |  | 170,224,116 |  | 169,630,880 |  | 170,224,116 |
Diluted basis | 170,610,356 |  | 171,556,357 |  | 170,610,356 |  | 171,556,357 |
Our common stock is without par value. Average Common Shares A reconciliation of the denominator (number of shares) in the calculations of basic and diluted earnings (loss) per common share was as follows:
| For the Three |  | For the Six |
| Months Ended |  | Months Ended |
| June 30, |  | June 30, |
| 2023 |  | 2022 |  | 2023 |  | 2022 |
Weighted-average shares, as used in basic calculation | 169,581,636 |  | 171,130,192 |  | 169,470,359 |  | 172,633,482 |
Shares to cover non-vested stock | 326,632 |  | 895,347 |  | 447,379 |  | 1,127,609 |
Average stock options outstanding during the period | 5,707 |  | 1,031,878 |  | 16,065 |  | 1,664,374 |
Assumed acquisition of shares with assumed |  |  |  |  |  |  |  |
proceeds and benefits from exercising stock |  |  |  |  |  |  |  |
options (at average market price for the period) | (5,469 | ) | (829,921 | ) | (13,335 | ) | (1,327,773 | )
Shares repurchasable from measured but |  |  |  |  |  |  |  |
unrecognized stock option expense | - |  | (12,772 | ) | - |  | (42,013 | )
Average deferred compensation shares | 589,001 |  | 492,269 |  | 571,484 |  | 506,740 |
Weighted-average shares, as used in diluted calculation (1) | 170,497,507 |  | 172,706,993 |  | 170,491,952 |  | 174,562,419 |
(1)Due to reporting a net loss for the six months ended June 30, 2023, basic shares were used in the diluted earnings per share calculation for this period as the use of diluted shares would have resulted in a lower loss per share. In the event the average market price of LNC common stock exceeds the issue price of stock options and the options have a dilutive effect to our earnings per share, such options will be shown in the table above. The income used in the calculation of our diluted earnings per share is our net income (loss), reduced by preferred stock dividends. This amount is presented on our Consolidated Statements of Income (Loss). We have participants in our deferred compensation plans who selected LNC stock as the measure for the investment return attributable to all or a portion of their deferral amounts. This obligation is settled in either cash or LNC stock pursuant to the applicable plan document. We exclude deferred units of LNC stock that are antidilutive from our diluted earnings per share calculation. The mark-to-market adjustment of these deferred units excluded from our diluted earnings per share calculation was $(2) million and $7 million for the three months ended June 30, 2023 and 2022, respectively, and $2 million and $7 million for the six months ended June 30, 2023 and 2022, respectively. AOCI The following summarizes the components and changes in AOCI (in millions):
| For the Six |
| Months Ended |
| June 30, |
| 2023 |  | 2022 |
Unrealized Gain (Loss) on Fixed Maturity AFS Securities and Certain Other |  |  |  |  |  |
Investments |  |  |  |  |  |
Balance as of beginning-of-year | $ | (8,916 | ) | $ | 9,616 |
Unrealized holding gains (losses) arising during the period |  | 803 |  |  | (19,853 | )
Change in foreign currency exchange rate adjustment |  | 120 |  |  | (371 | )
Change in future contract benefits and policyholder account balances |  | (82 | ) |  | 1,750 |
Income tax benefit (expense) |  | (199 | ) |  | 3,943 |
Less: |  |  |  |  |  |
Reclassification adjustment for gains (losses) included in net income (loss) |  | (707 | ) |  | (4 | )
Income tax benefit (expense) |  | 148 |  |  | 1 |
Balance as of end-of-period | $ | (7,715 | ) | $ | (4,912 | )
Unrealized Gain (Loss) on Derivative Instruments |  |  |  |  |  |
Balance as of beginning-of-year | $ | 388 |  | $ | (85 | )
Unrealized holding gains (losses) arising during the period |  | 230 |  |  | 126 |
Change in foreign currency exchange rate adjustment |  | (110 | ) |  | 373 |
Income tax benefit (expense) |  | (26 | ) |  | (104 | )
Less: |  |  |  |  |  |
Reclassification adjustment for gains (losses) included in net income (loss) |  | 43 |  |  | 25 |
Income tax benefit (expense) |  | (9 | ) |  | (5 | )
Balance as of end-of-period | $ | 448 |  | $ | 290 |
Market Risk Benefit Non-Performance Risk Gain (Loss) |  |  |  |  |  |
Balance as of beginning-of-year | $ | 1,741 |  | $ | 1,951 |
Adjustment arising during the period |  | 129 |  |  | 476 |
Income tax benefit (expense) |  | (28 | ) |  | (102 | )
Balance as of end-of-period | $ | 1,842 |  | $ | 2,325 |
Policyholder Liability Discount Rate Remeasurement Gain (Loss) |  |  |  |  |  |
Balance as of beginning-of-year | $ | 747 |  | $ | (1,265 | )
Adjustment arising during the period |  | (116 | ) |  | 1,933 |
Income tax benefit (expense) |  | 26 |  |  | (412 | )
Balance as of end-of-period | $ | 657 |  | $ | 256 |
Foreign Currency Translation Adjustment |  |  |  |  |  |
Balance as of beginning-of-year | $ | (34 | ) | $ | (14 | )
Foreign currency translation adjustment arising during the period |  | 8 |  |  | (18 | )
Income tax benefit (expense) |  | - |  |  | (1 | )
Balance as of end-of-period | $ | (26 | ) | $ | (33 | )
Funded Status of Employee Benefit Plans |  |  |  |  |  |
Balance as of beginning-of-year | $ | (278 | ) | $ | (219 | )
Adjustment arising during the period |  | (32 | ) |  | 13 |
Balance as of end-of-period | $ | (310 | ) | $ | (206 | )
‎ The following summarizes the reclassifications out of AOCI (in millions) and the associated line item on the Consolidated Statements of Comprehensive Income (Loss):
| For the Six |  |
| Months Ended |  |
| June 30, |  |
| 2023 |  |  | 2022 |  |
Unrealized Gain (Loss) on Fixed Maturity AFS |  |  |  |  |  |  |  |
Securities and Certain Other Investments |  |  |  |  |  |  |  |
Reclassification | $ | (707 | ) |  | $ | (4 | ) | Realized gain (loss)
Reclassification before income |  |  |  |  |  |  |  |
tax benefit (expense) |  | (707 | ) |  |  | (4 | ) | Income (loss) before taxes
Income tax benefit (expense) |  | 148 |  |  |  | 1 |  | Federal income tax expense (benefit)
Reclassification, net of income tax | $ | (559 | ) |  | $ | (3 | ) | Net income (loss)
Unrealized Gain (Loss) on Derivative Instruments |  |  |  |  |  |  |  |
Interest rate contracts | $ | - |  |  | $ | 1 |  | Net investment income
Interest rate contracts |  | 13 |  |  |  | (10 | ) | Interest and debt expense
Foreign currency contracts |  | 27 |  |  |  | 30 |  | Net investment income
Foreign currency contracts |  | 3 |  |  |  | 4 |  | Realized gain (loss)
Reclassifications before income |  |  |  |  |  |  |  |
tax benefit (expense) |  | 43 |  |  |  | 25 |  | Income (loss) before taxes
Income tax benefit (expense) |  | (9 | ) |  |  | (5 | ) | Federal income tax expense (benefit)
Reclassifications, net of income tax | $ | 34 |  |  | $ | 20 |  | Net income (loss)

X
- Definition This element is used to capture the complete disclosure pertaining to an entity's stock. Disclosure of the methodology and assumptions used in the reconciliation of earnings per share, which may include the individual income and share amount effects of all securities that affect EPS, the effect that has been given to preferred dividends in arriving at income available to common stockholders in computing basic EPS, securities that could dilute basic EPS in the future that would have been antidilutive. + References No definition available. + Details
Name: | lnc_ScheduleOfStockByClassAndEarningsPerShareReconciliationDisclosureTextBlock
Namespace Prefix: | lnc_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_StockholdersEquityNoteAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration